EU’s actions on biotech and biomanufacturing

The European Commission released in April 2024 its proposals for the European biotechnology and biomanufacturing sectors. Actions are based on the identified barriers and challenges still to be solved, among which are these are research and technology transfer, regulatory complexity, access to finance, skills, value chain obstacles, intellectual property, public acceptance and economic security

Concerns on the Munich District Court decisions on SPC

The first judgement on the Supplementary Protection Certificate (SPC) manufacturing waiver issued by the Munich District Court, Germany in October 2023 caused a deep concern among the generic and biosimilar industry, as highlighted in a note from Medicines for Europe


How to boost R&I and attract more talents

The political agreement reached by the European Council on the final text of the Recommendation on a European framework to attract and retain research, innovation and entrepreneurial talents in Europe updates the 2011 R1-R4 profiles for researchers, and introduces the European Charter for Researchers, a revision of the 2005 European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers

EU Parliament, a study on investments for Covid-19 Vaccines

A study prepared for the special COVI committee of the European Parliament shares light on how the great amount of funds for the development of Covid-19 vaccines was used for R&D and the expansion of the production capacity. Nine different vaccines have been examined, and comparisons have been also made with the US situation


  • Supplemento to n.1 - January 2024 NCF International 2024
  • Supplemento al n.8 - Ottobre 2023 NCF International 2023